NLRP3 and type 2 diabetes mellitus: Intiguingly, post-intervention LDL also inhibit WAT IL-1β-secretion induced by microbial LPS (Fig. 2G and H); (2) improves GIIS and postprandial fat metabolism (Fig. 3) in correlation with the post-intervention enrichment of RBC with EPA, DPA and mostly DHA (Fig. 4); and (3) eliminates most of the associations of WAT NLRP3 inflammasome priming (mRNA expression of NLRP3 and IL1B) and activation (IL-1β-secretion) with T2D and cardiometabolic risk factors including adiposity (Figs. 5, 6, and 7, Supplementary Figs. S5 and S6).